Lanreotide
Orphan Drug Cold Chain RequiredFDA Approved
Description
Lanreotide is a somatostatin analog that inhibits growth hormone and other hormones. It is approved for treatment of neuroendocrine tumors and acromegaly, making it relevant for multiple endocrine neoplasia syndromes. The drug provides sustained hormone suppression with monthly or extended dosing intervals.
Indications & Therapeutic Use
Acromegaly, gastroenteropancreatic neuroendocrine tumors, carcinoid syndrome, multiple endocrine neoplasia
Linked Diseases:
multiple endocrine neoplasia
D44.8D009377
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Lanreotide
| Generic Name | Lanreotide |
| Brands | 1 brand available |
| Active Ingredient | Lanreotide acetate |
| Drug Class | Acromegaly |
| Manufacturer | Ipsen |
| Dosage Forms | Subcutaneous injection, 60mg, 90mg, 120mg prefilled syringe |
| Medical Code | H01CB03 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00353496 |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes